Study offers insight into state Medicaid coverage for anti-obesity drugs

NewsGuard 100/100 Score

Mounting evidence suggests that FDA-approved weight loss medications, such as Wegovy, not only help patients lose weight but also protect against complications from obesity such as cardiovascular disease. In 2021, 40 percent of patients enrolled in Medicaid had obesity. The high cost of these drugs has raised concerns about affordability, both for patients and public insurance programs. 

Researchers from Brigham and Women's Hospital, a founding member of Mass General Brigham, studied state Medicaid coverage policies for anti-obesity medications from 2011 through the first quarter of 2023, finding that 10 out of 47 states covered at least one anti-obesity medication. Their results are published today in JAMA. "At least 1 in 5 states offer coverage for one or more anti-obesity medications, and that trend has increased in recent years," said corresponding author Benjamin Rome, MD, MPH, of the Division of Pharmacoepidemiology and Pharmacoeconomics. "Newer medications are remarkably effective, but they are quite expensive, which is a major concern for states when deciding whether to cover these drugs. States or the federal government need to negotiate lower prices to help ensure access to effective anti-obesity drugs for vulnerable Medicaid patients while addressing budgetary concerns." 

Journal reference:

Liu, B. Y., & Rome, B. N. (2024). State Coverage and Reimbursement of Antiobesity Medications in Medicaid. JAMA.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Can monitoring and encouraging physical activity through phone-based apps improve glycemic control and weight loss in type 2 diabetes patients?